Tue, July 17, 2012
Mon, July 16, 2012
[ Mon, Jul 16th 2012 ]: Market Wire
30 a.m. ET
Fri, July 13, 2012
Thu, July 12, 2012
Wed, July 11, 2012
Tue, July 10, 2012
Mon, July 9, 2012
Fri, July 6, 2012
Thu, July 5, 2012
Wed, July 4, 2012
[ Wed, Jul 04th 2012 ]: Market Wire
Warnex Announces Refinancing
Tue, July 3, 2012
Mon, July 2, 2012
Sun, July 1, 2012
Fri, June 29, 2012
Thu, June 28, 2012
Wed, June 27, 2012
Tue, June 26, 2012
Mon, June 25, 2012
[ Mon, Jun 25th 2012 ]: Market Wire
Myths or Factsa" Campaign
Sun, June 24, 2012
Sat, June 23, 2012
Fri, June 22, 2012

Isis Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference


  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. annual-jmp-securities-healthcare-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

Isis Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference -- CARLSBAD, Calif., July 5, 2012 /PRNewswire/ --

Isis Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference

[ ]

CARLSBAD, Calif., July 5, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: [ ISIS ]), the leader in antisense therapeutics, today announced that management will present a company overview at the 7th Annual JMP Securities Healthcare Conference on Thursday, July 12, 2012 at 2:00 p.m. ET at the Peninsula Hotel in New York.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, [ www.isispharm.com ].  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at [ www.isispharm.com ].

SOURCE Isis Pharmaceuticals, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.isispharm.com ]


Publication Contributing Sources